Scientist I, Process Development
Arcturus Therapeutics Inc
Summary
We are seeking a motivated, collaborative Scientist I to join our Formulation and Process Development team. This lab-based role will support the development, optimization, characterization, and scale-up of lipid nanoparticle (LNP) formulations for mRNA payloads, and will provide formulation support for in vivo studies. The ideal candidate has hands-on experience with LNPs or related nucleic-acid delivery systems and will design and run experiments, interpret data, troubleshoot, and work cross-functionally to advance programs from early screening and in vivo evaluation through manufacturing readiness.
Job description
Position Summary
We are seeking a motivated, collaborative Scientist I to join our Formulation and Process Development team. This lab-based role will support the development, optimization, characterization, and scale-up of lipid nanoparticle (LNP) formulations for mRNA payloads, and will provide formulation support for in vivo studies. The ideal candidate has hands-on experience with LNPs or related nucleic-acid delivery systems and will design and run experiments, interpret data, troubleshoot, and work cross-functionally to advance programs from early screening and in vivo evaluation through manufacturing readiness.
Key Responsibilities
- Design and execute studies to develop and optimize LNP formulations for mRNA evaluating lipid composition, lipid-to-RNA and N/P ratios, buffer, pH, excipients, and process conditions.
- Support development of product specific LNP unit operations, including phase preparation, nanoparticle formation, dilution, buffer exchange, concentration, filtration, and frozen or lyophilized storage.
- Apply Design of Experiments and other statistical approaches to understand composition–process–product relationships.
- Characterize LNPs, interpret results and troubleshoot sample or method issues.
- Run stability, freeze-thaw, hold-time, scale-up, and robustness studies, and trend data to identify critical quality attributes.
- Troubleshoot formulation and process issues, and support scale-up, technology transfer, manufacturing investigations, and non-GMP/GMP activities as needed.
- Author protocols, technical reports, and presentations.
- Partner with in vivo study teams on study design and formulation requests, and prepare, dilute, sterile-filter, and fill LNP test articles for internal in vitro and in vivo studies using aseptic technique within defined hold times.
- Verify dose formulations meet in vivo requirements, provide supporting documentation, coordinate test article labeling, storage, and shipment, and correlate physicochemical attributes with in vivo performance to guide formulation selection.
- Contribute to lab operations and perform other duties as assigned.
Required Qualifications
- PhD in Pharmaceutical Sciences, Chemical Engineering, Bioengineering, Biomedical Engineering, Chemistry, Biochemistry, Materials Science, or a related discipline.
- Scientist I: 0–2 year of relevant experience.
- Hands-on experience formulating, processing, or characterizing LNPs, liposomes, or related delivery systems with nucleic-acid payloads, including methods such as DLS, size/PDI, encapsulation efficiency, and RNA quantitation.
- Working knowledge of lipid-based drug delivery, colloidal systems, and factors affecting nanoparticle stability and performance.
- Strong experimental design, data analysis, troubleshooting, documentation, and communication skills, with the ability to work independently and in a multidisciplinary team.
Preferred Qualifications
- Experience supporting in vitro and in vivo studies, including dose formulation preparation, aseptic technique, and test-article requirements.
- Experience correlating formulation attributes with in vivo performance, and proficiency with data analysis software such as JMP or GraphPad Prism.
- Experience with or working knowledge of peptide, antibody, or other nanoparticle-ligand conjugation techniques, and associated characterization and purification techniques.
- Experience with or working knowledge of analytical instrumentation such as HPLC.
Requirements
- PhD in Pharmaceutical Sciences, Chemical Engineering, Bioengineering, Biomedical Engineering, Chemistry, Biochemistry, Materials Science, or a related discipline
- 0–2 years of relevant experience
- Hands-on experience formulating, processing, or characterizing LNPs, liposomes, or related delivery systems with nucleic-acid payloads
- Experience with methods such as DLS, size/PDI, encapsulation efficiency, and RNA quantitation
- Working knowledge of lipid-based drug delivery, colloidal systems, and factors affecting nanoparticle stability and performance
- Strong experimental design, data analysis, troubleshooting, documentation, and communication skills
- Ability to work independently and in a multidisciplinary team
Benefits
- Medical, Dental & Vision
- Employee Stock Purchase Program
- Competitive salaries
- Bonus plans
- Stock Options
- Free snacks and beverages
- Health and Wellness programs
- Anniversary cash awards
- Referral Bonuses
- Company-sponsored events
Company overview
Arcturus Therapeutics Holdings Inc. is a pioneering American biotechnology company specializing in RNA medicines, founded in 2013 and headquartered in San Diego, California. The company focuses on the discovery, development, and commercialization of therapeutics for rare diseases and infectious diseases through its innovative RNA technology platforms. Arcturus has developed proprietary lipid nanoparticle delivery systems called LUNAR® and STARR® mRNA technology, enabling efficient delivery of various nucleic acid medicines including messenger RNA (mRNA), small interfering RNA (siRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company's pipeline includes treatments for rare conditions such as ornithine transcarbamylase deficiency (OTCD) and cystic fibrosis, along with vaccine candidates for COVID-19 and influenza. Arcturus gained significant recognition for developing KOSTAIVE®, the world's first approved self-amplifying mRNA COVID-19 vaccine, authorized in Japan and the European Union. With a workforce of approximately 124-337 employees and publicly traded on NASDAQ under the symbol ARCT, the company maintains strategic collaborations with global partners including CSL Seqirus and operates a joint venture in Japan called ARCALIS for mRNA vaccine manufacturing.